EUVIMEDEUVIMED entdecken
Crossref

Evaluation of safety criteria for enoxaparin bridging in patients with left ventricular assist devices in an outpatient care setting

Lee D Lam, Lawrence S Czer, Carmelita Runyan, Ieeshiah Otarola, Jason Jang, Jason Lau, Mignon Gau, Katrina Hernandez, Tram Ngo, Mario Aguillon, Newman Huie, Julie W Chen und 3 weitere

Artificial Organs · 2025

DOI: 10.1111/aor.14900 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Lee D Lam und 14 weiteren Autor:innen. Beteiligte Einrichtung: Cedars Sinai Comprehensive Transplant Center, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Enoxaparin, Anticoagulants, Hemorrhage, Thrombosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Appropriate anticoagulation is crucial for the success of left ventricular assist device patients. Currently, there is no consensus on the optimal management of their subtherapeutic INR in ambulatory setting. Our goal is to evaluate both the short‐term adverse events and long‐term outcomes of enoxaparin bridging at a major transplant center, following the implementation of bridging safety criteria.

Methods

In total, 85 patients' medical records were reviewed between 7/2019 and 5/2022, with 51 patients meeting safety criteria were bridged with enoxaparin and 34 non‐bridged. The primary endpoint was the occurrence of major bleeding/thrombosis events within 30 days of bridging. The secondary endpoint was freedom from events 30 days after enoxaparin initiation and overall patient survivability until the last follow‐up.

Results

Within 30 days, no major bleeding/thrombotic events were noted. After 30 days, the major bleeding rate was 5.8% in bridged vs. 11.8% in non‐bridged patients ( p = 0.02). Overall, 3‐year survival was 78% in the bridged vs. 49% in non‐bridged patients ( p < 0.001). In patients with no events, 3‐year survival was 80% in bridged vs. 58% in non‐bridged ( p < 0.001). In the patients with bleeding events, 3‐year survival was 55% in bridged vs. 51% in non‐bridged ( p = 0.11). At 1 year, freedom from bleeding in the bridged patients was 81% in patients with no events vs. 0% in those with an event ( p < 0.0001).

Conclusion

When eligibility criteria for safe bridging were applied, the use of enoxaparin bridging was associated with no major bleeding/thrombotic events during bridging and improved 3‐year survival in LVAD patients. Economically, using outpatient enoxaparin resulted in substantial healthcare savings, fewer readmissions, and improved quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EnoxaparinAnticoagulantsHemorrhageThrombosisHeart-Assist DevicesRetrospective StudiesHumansMaleFemaleAdultMiddle AgedAgedAmbulatory Care

Stichwörter der Autor:innen

anticoagulationeligibility criteriaenoxaparinleft ventricular assist devices (LVAD)

Substanzen

EnoxaparinAnticoagulants

Autor:innen und Institutionen

  • Cedars Sinai Comprehensive Transplant Center, Los Angeles, California, USA.
  • Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, California, USA.
  • Department of Pharmacy, Cedars Sinai Medical Center, Los Angeles, California, USA.
  • Department of Pathology, Cedars Sinai Medical Center, Los Angeles, California, USA.

ORCID-Profile: Oksana Volod

Zitieren

APA

Lam, L. D., Czer, L. S., Runyan, C., Otarola, I., Jang, J., Lau, J., Gau, M., Hernandez, K., Ngo, T., Aguillon, M., Huie, N., Chen, J. W., Cole, R., Moriguchi, J., & Volod, O. (2025). Evaluation of safety criteria for enoxaparin bridging in patients with left ventricular assist devices in an outpatient care setting. Artificial Organs. https://doi.org/10.1111/aor.14900

Vancouver

Lam LD, Czer LS, Runyan C, Otarola I, Jang J, Lau J, et al. Evaluation of safety criteria for enoxaparin bridging in patients with left ventricular assist devices in an outpatient care setting. Artificial Organs. 2025. doi:10.1111/aor.14900

BibTeX
@article{Lam2025,
  author = {Lam, Lee D and Czer, Lawrence S and Runyan, Carmelita and Otarola, Ieeshiah and Jang, Jason and Lau, Jason and Gau, Mignon and Hernandez, Katrina and Ngo, Tram and Aguillon, Mario and Huie, Newman and Chen, Julie W and Cole, Robert and Moriguchi, Jaime and Volod, Oksana},
  title = {Evaluation of safety criteria for enoxaparin bridging in patients with left ventricular assist devices in an outpatient care setting},
  journal = {Artificial Organs},
  year = {2025},
  doi = {10.1111/aor.14900}
}
Kostenlos starten →